| 2025 | 2024 | 2023 | ||||
|---|---|---|---|---|---|---|
| Revenue | 1,2 Md € | +3.7% | 1,1 Md € | +172.3% | 419,1 M € | |
| EBITDA | 28,1 M € | -17.9% | 34,2 M € | +41.0% | 24,2 M € | |
| Operating profit | 25,3 M € | -18.5% | 31,0 M € | +55.3% | 20,0 M € | |
| Profit/loss | 18,9 M € | -28.7% | 26,5 M € | +75.9% | 15,1 M € | |
| Equity | 12,4 M € | -24.8% | 16,5 M € | +10.4% | 14,9 M € | |
| Total assets | 153,7 M € | +33.6% | 115,0 M € | -37.4% | 183,8 M € | |
| Cash | — | — | 63,7 M € | |||
| Debts | 136,9 M € | +45.0% | 94,4 M € | -42.2% | 163,3 M € | |
| Staff | 93,6 | 86,3 | 82,3 | |||
Source: Belgian Official Gazette
Private limited company · Hoegaarden · incorporated on 18/03/2022 · 93,6 ETP
Private limited company profitable but thinly capitalised.
Solid counterparty for a standard engagement.
Key indicators
CYTIVA BELGIUM is a Private limited company incorporated in 2022. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Hoegaarden. It employs on average 93,6 ETP workers (FTE).